Skip to content
10-K

Annual Report

FATE THERAPEUTICS, INC. FATE

0001193125-26-073699

← back to feed
Filed
Feb 26, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Feb 19, 2026 116.26M sh
Shares Diluted FY 2025 · Dec 31, 2025 118.79M sh
Shares Diluted FY 2025 · Dec 31, 2024 113.69M sh
Capex FY 2025 · Dec 31, 2025 $5.95M
Capex FY 2025 · Dec 31, 2024 $730K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$106.08M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$122.87M
Short Term Investments FY 2025 · Dec 31, 2025 $157.03M
Short Term Investments FY 2025 · Dec 31, 2024 $243.01M
Cash And Equivalents FY 2025 · Dec 31, 2025 $46.63M
Cash And Equivalents FY 2025 · Dec 31, 2024 $36.06M
Stockholders Equity FY 2025 · Dec 31, 2025 $207.18M
Stockholders Equity FY 2025 · Dec 31, 2024 $318.73M
Stockholders Equity FY 2025 · Dec 31, 2023 $368.42M
Current Liabilities FY 2025 · Dec 31, 2025 $36.07M
Current Liabilities FY 2025 · Dec 31, 2024 $38.52M
Current Assets FY 2025 · Dec 31, 2025 $208.7M
Current Assets FY 2025 · Dec 31, 2024 $291.91M
Total Assets FY 2025 · Dec 31, 2025 $318.94M
Total Assets FY 2025 · Dec 31, 2024 $440.69M
Eps Diluted FY 2025 · Dec 31, 2025 −$1.15
Eps Diluted FY 2025 · Dec 31, 2024 −$1.64
Eps Basic FY 2025 · Dec 31, 2025 −$1.15
Eps Basic FY 2025 · Dec 31, 2024 −$1.64
Sga Expense FY 2025 · Dec 31, 2025 $46.52M
Sga Expense FY 2025 · Dec 31, 2024 $74.17M
Rd Expense FY 2025 · Dec 31, 2025 $107.83M
Rd Expense FY 2025 · Dec 31, 2024 $135M
Net Income FY 2025 · Dec 31, 2025 −$136.32M
Net Income FY 2025 · Dec 31, 2024 −$186.26M
Operating Income FY 2025 · Dec 31, 2025 −$147.7M
Operating Income FY 2025 · Dec 31, 2024 −$210.28M
Revenue FY 2025 · Dec 31, 2025 $6.65M
Revenue FY 2025 · Dec 31, 2024 $13.63M